Impact of Brokerage Rating on Shire PLC(SHPG)

Many Shire PLC(SHPG) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. Shire PLC (ADR) was Initiated by Societe Generale to Buy on Dec 2, 2016.

Shire PLC (ADR) Last issued its quarterly earnings results on Nov 1, 2016. The company reported $3.17 EPS for the quarter, beating the analyst consensus estimate by $ 0.01. Analyst had a consensus of $3.16. The company had revenue of $3452.00 million for the quarter, compared to analysts expectations of $3564.95 million. The companys revenue was up 108.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.24 EPS.

Shire plc (NASDAQ:SHPG) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1.36 by 11 Brokerage Firm. 9 Wall Street Firms have rated the stock as a strong buys. 2 Brokerage Firms have advised hold.

Shire plc (NASDAQ:SHPG): 9 Analyst have given the stock of Shire plc (NASDAQ:SHPG) a near short term price target of $247.56. The standard deviation reading, which is a measure by which the stock price is expected to swing away from the mean estimate, is at $43.4. The higher price target estimate is at $325 while the lower price estimates are fixed at $182.

Shire plc (NASDAQ:SHPG) rose 1.04% or 1.77 points on Tuesday and made its way into the gainers of the day. After trading began at $169.58 the stock was seen hitting $172.68 as a peak level and $169.19 as the lowest level. The stock ended up at $172.32. The daily volume was measured at 867,884 shares. The 52-week high of the share price is $209.22 and the 52-week low is $150.055. The company has a market cap of $51,960 million.

Shire Pharmaceuticals Group plc is a specialty pharmaceutical company focused primarily on two therapeutic areas: central nervous system disorders and metabolic bone diseases. (press release)

Shire

Share this post

Post Comment